drugset / Trial / NCT06869278
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Phase 1
Withdrawn
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.
Timeline
- Start
- 2025-06-17
- Primary completion
- 2025-06-17
- Completion
- 2025-06-17
Outcome
Outcome not reported
Stopped: “Legend discontinues the development of the IMP.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-AIO | Cell therapy | — | Other |